Literature DB >> 6150154

Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate.

F Labrie, A Belanger, A Dupont, J Emond, Y Lacoursiere, G Monfette.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6150154     DOI： 10.1016/s0140-6736(84)91521-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Informed consent.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-09

2.  Ocular toxicity of Anandron in patients treated for prostatic cancer.

Authors:  C Harnois; M Malenfant; A Dupont; F Labrie
Journal:  Br J Ophthalmol       Date:  1986-06       Impact factor: 4.638

Review 3.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

4.  Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration.

Authors:  L Rousseau; A Dupont; F Labrie; M Couture
Journal:  Arch Sex Behav       Date:  1988-02

Review 5.  Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer.

Authors:  J T Isaacs; N Kyprianou
Journal:  Urol Res       Date:  1987

Review 6.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

Review 7.  Hormonal therapy for stage D cancer of the prostate.

Authors:  M R Gudziak; A Y Smith
Journal:  West J Med       Date:  1994-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.